SARS-CoV-2 infects gut cells
Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that...
February 17, 2022
A message from our CEO
Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are...
February 17, 2022
Organoids for genetic disorders
Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology...
February 17, 2022
HUB on Financial Times
On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research".
February 17, 2022
PDX organoids in drug development
San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the...
February 17, 2022
Organoids-on-a-chip
Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid...
February 17, 2022
Epistem license HUB Technology
Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in...
February 17, 2022
HUB PDOs now at CrownBio
San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology...
February 17, 2022
New partner: CrownBio
March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a strategic partnership...
February 17, 2022
New partner: Yamaha Motor
February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide solutions that...
